100 related articles for article (PubMed ID: 27984038)
1. Increased Expression of PLS3 Correlates with Better Outcome in Sézary Syndrome.
Boonk SE; Zoutman WH; Putter H; Ram-Wolff C; Felcht M; Klemke CD; Ranki A; Quaglino P; Whittaker S; Bagot M; Willemze R; Vermeer MH
J Invest Dermatol; 2017 Mar; 137(3):754-757. PubMed ID: 27984038
[No Abstract] [Full Text] [Related]
2. Use of PLS3, Twist, CD158k/KIR3DL2, and NKp46 gene expression combination for reliable Sézary syndrome diagnosis.
Michel L; Jean-Louis F; Begue E; Bensussan A; Bagot M
Blood; 2013 Feb; 121(8):1477-8. PubMed ID: 23429988
[No Abstract] [Full Text] [Related]
3. T-plastin (PLS3) gene expression differentiates Sézary syndrome from mycosis fungoides and inflammatory skin diseases and can serve as a biomarker to monitor disease progression.
Tang N; Gibson H; Germeroth T; Porcu P; Lim HW; Wong HK
Br J Dermatol; 2010 Feb; 162(2):463-6. PubMed ID: 19995369
[TBL] [Abstract][Full Text] [Related]
4. Promoter-Specific Hypomethylation Is Associated with Overexpression of PLS3, GATA6, and TWIST1 in the Sezary Syndrome.
Wong HK; Gibson H; Hake T; Geyer S; Frederickson J; Marcucci G; Caligiuri MA; Porcu P; Mishra A
J Invest Dermatol; 2015 Aug; 135(8):2084-2092. PubMed ID: 25806852
[TBL] [Abstract][Full Text] [Related]
5. Regulation of T-plastin expression by promoter hypomethylation in primary cutaneous T-cell lymphoma.
Jones CL; Ferreira S; McKenzie RC; Tosi I; Caesar JA; Bagot M; Whittaker SJ; Mitchell TJ
J Invest Dermatol; 2012 Aug; 132(8):2042-9. PubMed ID: 22495182
[TBL] [Abstract][Full Text] [Related]
6. Inducible expression and pathophysiologic functions of T-plastin in cutaneous T-cell lymphoma.
Bégué E; Jean-Louis F; Bagot M; Jauliac S; Cayuela JM; Laroche L; Parquet N; Bachelez H; Bensussan A; Courtois G; Michel L
Blood; 2012 Jul; 120(1):143-54. PubMed ID: 22627769
[TBL] [Abstract][Full Text] [Related]
7. The mutational landscape of cutaneous T cell lymphoma and Sézary syndrome.
da Silva Almeida AC; Abate F; Khiabanian H; Martinez-Escala E; Guitart J; Tensen CP; Vermeer MH; Rabadan R; Ferrando A; Palomero T
Nat Genet; 2015 Dec; 47(12):1465-70. PubMed ID: 26551667
[TBL] [Abstract][Full Text] [Related]
8. MicroRNA profiling reveals that miR-21, miR486 and miR-214 are upregulated and involved in cell survival in Sézary syndrome.
Narducci MG; Arcelli D; Picchio MC; Lazzeri C; Pagani E; Sampogna F; Scala E; Fadda P; Cristofoletti C; Facchiano A; Frontani M; Monopoli A; Ferracin M; Negrini M; Lombardo GA; Caprini E; Russo G
Cell Death Dis; 2011 Apr; 2(4):e151. PubMed ID: 21525938
[TBL] [Abstract][Full Text] [Related]
9. PLS3 expression and SMA phenotype: a commentary on correlation of PLS3 expression with disease severity in children with spinal muscular atrophy.
Nishio H
J Hum Genet; 2014 Feb; 59(2):64-5. PubMed ID: 24284364
[No Abstract] [Full Text] [Related]
10. NOTCH1 signaling as a therapeutic target in Sézary syndrome.
van der Fits L; Qin Y; Out-Luiting JJ; Vermeer KG; Whittaker S; van Es JH; Tensen CP; Vermeer MH
J Invest Dermatol; 2012 Dec; 132(12):2810-7. PubMed ID: 22718117
[TBL] [Abstract][Full Text] [Related]
11. Genomic profiling of Sézary syndrome identifies alterations of key T cell signaling and differentiation genes.
Wang L; Ni X; Covington KR; Yang BY; Shiu J; Zhang X; Xi L; Meng Q; Langridge T; Drummond J; Donehower LA; Doddapaneni H; Muzny DM; Gibbs RA; Wheeler DA; Duvic M
Nat Genet; 2015 Dec; 47(12):1426-34. PubMed ID: 26551670
[TBL] [Abstract][Full Text] [Related]
12. Aberrant expression of the tyrosine kinase receptor EphA4 and the transcription factor twist in Sézary syndrome identified by gene expression analysis.
van Doorn R; Dijkman R; Vermeer MH; Out-Luiting JJ; van der Raaij-Helmer EM; Willemze R; Tensen CP
Cancer Res; 2004 Aug; 64(16):5578-86. PubMed ID: 15313894
[TBL] [Abstract][Full Text] [Related]
13. Photopheresis does not improve survival in Sézary syndrome patients with bone marrow involvement.
de Misa RF; Harto A; Azaña JM; Belmar P; Díez E; Ledo A
J Am Acad Dermatol; 2005 Jul; 53(1):171-2. PubMed ID: 15965446
[No Abstract] [Full Text] [Related]
14. Aberrant expression of T-plastin in Sezary cells.
Su MW; Dorocicz I; Dragowska WH; Ho V; Li G; Voss N; Gascoyne R; Zhou Y
Cancer Res; 2003 Nov; 63(21):7122-7. PubMed ID: 14612505
[TBL] [Abstract][Full Text] [Related]
15. Aberrant expression of plastin-3 via copy number gain induces the epithelial-mesenchymal transition in circulating colorectal cancer cells.
Sugimachi K; Yokobori T; Iinuma H; Ueda M; Ueo H; Shinden Y; Eguchi H; Sudo T; Suzuki A; Maehara Y; Mori M; Mimori K
Ann Surg Oncol; 2014 Oct; 21(11):3680-90. PubMed ID: 24217791
[TBL] [Abstract][Full Text] [Related]
16. Loss of β-arrestin-2 gene and possible functional consequences on Sezary Syndrome.
Cristofoletti C; Bresin A; Caprini E; Russo G; Narducci MG
Cell Cycle; 2019 Jun; 18(11):1292-1294. PubMed ID: 31106661
[TBL] [Abstract][Full Text] [Related]
17. Genetic rearrangements result in altered gene expression and novel fusion transcripts in Sézary syndrome.
Iżykowska K; Przybylski GK; Gand C; Braun FC; Grabarczyk P; Kuss AW; Olek-Hrab K; Bastidas Torres AN; Vermeer MH; Zoutman WH; Tensen CP; Schmidt CA
Oncotarget; 2017 Jun; 8(24):39627-39639. PubMed ID: 28489605
[TBL] [Abstract][Full Text] [Related]
18. Allelotyping in mycosis fungoides and Sézary syndrome: common regions of allelic loss identified on 9p, 10q, and 17p.
Scarisbrick JJ; Woolford AJ; Russell-Jones R; Whittaker SJ
J Invest Dermatol; 2001 Sep; 117(3):663-70. PubMed ID: 11564174
[TBL] [Abstract][Full Text] [Related]
19. Novel biomarkers, dysregulated epigenetics, and therapy in cutaneous T-cell lymphoma.
Wong HK
Discov Med; 2013 Sep; 16(87):71-8. PubMed ID: 23998443
[TBL] [Abstract][Full Text] [Related]
20. Overexpression of c-myb in leukaemic and non-leukaemic variants of cutaneous T-cell lymphoma.
Poenitz N; Simon-Ackermann J; Gratchev A; Qadoumi M; Klemke CD; Stadler R; Kremer A; Radenhausen M; Henke U; Assaf C; Utikal J; Goerdt S; Dippel E
Dermatology; 2005; 211(2):84-92. PubMed ID: 16088151
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
